Up to one hundred percent
The new vaccine from COVID-19 of the American company Novavax has shown high efficiency
Marina Astvatsaturyan, Echo of Moscow
Little-known as a vaccine manufacturer, Novavax announced the results of clinical trials involving 30,000 people in the United States and Mexico. We are talking about a protein vaccine, for the creation of which a technology was used that is different from those that produced other anti-covid vaccines approved to date.
The Novavax vaccine is based on the protein of the SARS-CoV-2 virus, the introduction of which into the body promotes the development of an immune response that protects against the symptomatic course of COVID-19 with an efficiency of 90.4%, and from the disease in moderate and severe form – by 100%, the company's press release reports.
Tests with eight variants of the coronavirus that causes covid showed an efficiency of 93.2%. The vaccine is recognized as safe and well tolerated. Novavax plans to apply to the U.S. Food and Drug Administration (FDA) and other agencies for approval for use in emergency situations in the third quarter, as soon as it completes all the formalities certifying regulators that the vaccine meets the requirements for products that have passed clinical trials.
The current announcement marks the beginning of a new stage for a company that was on the verge of survival. Novavax began developing its vaccine in January 2020 and in July of the same year received support of one and a half billion dollars under the government program Operation Warp Speed, which aims to facilitate and accelerate the development, production and distribution of vaccines, therapeutic and diagnostic tools against COVID-19.
Antitussive vaccines approved in the West work by delivering genetic material to the body for the production of a spike protein that is on the surface of the SARS-CoV-2 virus and causes an immune system reaction. But the Novavax vaccine instead delivers the protein itself. It is located on nanoparticles as part of a special solution based on the foaming surfactant saponin, which serves as an adjuvant, that is, enhances the immune response.
Such protein technology has been used for the production of vaccines for a long time, for example, the hepatitis B vaccine. In the current trials, two-thirds of participants at 113 locations in the U.S. and six in Mexico received two doses of the vaccine three weeks apart. A third of the participants received a placebo. In the period from January 25 to April 30, 77 cases of covid were noted among the test participants, 63 of them in the placebo group, 14 cases among the vaccinated were moderate.
Portal "Eternal youth" http://vechnayamolodost.ru